Dabigatran is used for treatment of deep vein thrombosis and pulmonary embolism and for recurrence prevention. A specific feature of the dabigatran and edoxaban regimens: first 5–10 days of parenteral anticoagulation (LMWH), then a switch to dabigatran 150 mg twice daily. CHEST 2022 lists DOACs as first-line therapy for most VTE patients; warfarin is reserved for antiphospholipid syndrome, severe renal impairment, and active cancer (where direct factor Xa inhibitors are preferred).

Sources

Practical notes

Timing and administration

Taken twice daily 12 hours apart with or without food. Swallow the capsule whole – do not break or open it: removing the shell raises active-drug bioavailability and may increase bleeding risk by up to 75 percent. Keep the drug in the original blister pack: dabigatran is moisture-sensitive and loses activity if transferred to a pill organizer.

Dose titration

Dose is not titrated by effect, it is selected upfront: 150 mg twice daily in AF with CHA2DS2-VA ≥ 2 in patients under 80 with eGFR above 50 mL/min/1.73 m²; 110 mg twice daily in patients over 80, with concomitant verapamil, with eGFR 30–50 mL/min/1.73 m², or with ≥ 3. In VTE always 150 mg twice daily after 5–10 days of parenteral therapy.

Monitoring

Routine INR, PT, and aPTT monitoring is not required. Before initiation check eGFR, hemoglobin, platelets, and liver enzymes. Repeat eGFR at 6 months, then yearly in stable patients and every 3 months at eGFR below 60 mL/min/1.73 m². In emergencies, dabigatran activity is measured with diluted thrombin time (dTT) or ecarin clotting time; aPTT gives only a rough estimate (a normal aPTT does not exclude therapeutic concentration).

Special situations

For elective surgery with low bleeding risk, hold for 24 hours (eGFR above 80), 36 hours (eGFR 50–80), 48–72 hours (eGFR below 50). For high bleeding risk, double the intervals. Restart 24–48 hours after stable hemostasis. In life-threatening bleeding, give idarucizumab 5 g intravenously – hemostasis is restored in minutes. St. John's Wort induces P-glycoprotein and reduces dabigatran concentration by 20–30 percent: patients are instructed to avoid it.

Common myths

Myth: “DOACs have no antidote”. Fact: idarucizumab is a specific antidote to dabigatran, approved by and and available in Russia. Andexanet alfa is an antidote to direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban).

Myth: “dabigatran does not need INR monitoring – so no need to see the doctor”. Fact: INR is not needed, but assessment and renal function checks every 3–12 months are mandatory. A drop in eGFR below 30 mL/min/1.73 m² requires immediate discontinuation and a switch.

Myth: “the capsule can be opened and mixed with food for a child or older patient”. Fact: breaking the capsule shell raises bioavailability by 75 percent and increases bleeding risk. Dabigatran is taken whole.

Frequently asked

What is dabigatran used for?

dabigatran is evaluated for the following indications with varying evidence strength: Non-valvular atrial fibrillation (evidence tier A), Venous thromboembolism (evidence tier A), Anticoagulation for mechanical heart valve (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of dabigatran?

Common side effects of dabigatran (≥ 1 in 100): Dyspepsia, gastritis-like symptoms (higher with dabigatran than other DOACs – linked to tartaric acid in the capsule), GI bleeding, Epistaxis, bruising, Anemia. See the Safety section for uncommon and serious reactions.

Is dabigatran safe during pregnancy?

FDA category C. FDA category C. Pregnancy data are limited. When anticoagulation is indicated (VTE, AF) during pregnancy, low-molecular-weight heparins are preferred: they do not cross the placenta and have a larger clinical record. Dabigatran is used only when alternatives are unavailable.

Is dabigatran compatible with breastfeeding?

Human breast milk data on dabigatran are absent. During lactation, anticoagulation is switched to warfarin or LMWH when therapy is required.

Who should not take dabigatran?

dabigatran is contraindicated in: Active clinically significant bleeding; Lesions with high bleeding risk (GI ulcer, recent intracranial hemorrhage, esophageal varices); eGFR below 30 mL/min/1.73 m²; Mechanical heart valve prosthesis; Severe hepatic impairment. Full list in the Safety section.

Does dabigatran carry an FDA boxed warning?

FDA boxed warning: premature discontinuation of dabigatran increases the risk of thrombotic events. Planned discontinuation requires transition to another anticoagulant if the indication remains. Spinal and epidural hematomas are possible in patients with neuraxial anesthesia or spinal puncture – prolonged monitoring and individualized timing between procedure and dosing are required.

“DOACs have no antidote”

idarucizumab is a specific antidote to dabigatran, approved by FDA and EMA and available in Russia. Andexanet alfa is an antidote to direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban).

“dabigatran does not need INR monitoring – so no need to see the doctor”

INR is not needed, but assessment and renal function checks every 3–12 months are mandatory. A drop in eGFR below 30 mL/min/1.73 m² requires immediate discontinuation and a switch.

“the capsule can be opened and mixed with food for a child or older patient”

breaking the capsule shell raises bioavailability by 75 percent and increases bleeding risk. Dabigatran is taken whole.

dabigatran

Mechanism of action

Indications

Non-valvular atrial fibrillation

Venous thromboembolism

Anticoagulation for mechanical heart valve

Practical notes

Timing and administration

Dose titration

Monitoring

Special situations

Common myths

Drug–nutrient interactions

St. John's Wort

Drug–drug interactions

dronedarone

Safety

Contraindications

Serious adverse effects

Common adverse effects

Uncommon adverse effects

PregnancyFDA C

Breastfeeding

Frequently asked